| 焦亚龙,任艳红,张亚芹,等.克岩胶囊联合介入治疗原发性肝癌病人的疗效及对糖类抗原 199、癌胚抗原水平的影响[J].安徽医药,2023,27(6):1135-1139. |
| 克岩胶囊联合介入治疗原发性肝癌病人的疗效及对糖类抗原 199、癌胚抗原水平的影响 |
| Effect of Keyan capsule combined with interventional therapy on the level of CA199 and CEA in patients with primary liver cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2023.06.017 |
| 中文关键词: 肝肿瘤 化学栓塞，治疗性 肝动脉 克岩胶囊 介入治疗 糖类抗原 199 癌胚抗原 |
| 英文关键词: Liver neoplasms Chemoembolization, therapeutic Hepatic artery Keyan capsule Interventional therapy CA199 CEA |
| 基金项目:河北省中医药管理局科研计划项目( 2022504) |
|
| 摘要点击次数: 747 |
| 全文下载次数: 257 |
| 中文摘要: |
| 目的分析克岩胶囊联合介入治疗对原发性肝癌病人的疗效及对糖类抗原 199、癌胚抗原水平的影响。方法选取 2019年 8月至 2021年 8月河北中医肝病医院医院收治的 176例原发性肝癌病人作为研究对象，采用随机数字表法分为对照组与研究组，各 88例。对照组进行介入治疗，研究组在对照组的基础上使用克岩胶囊治疗，治疗 3疗程后对比两组纤溶功能、凝血功能、 T细胞亚群、糖类抗原 199、癌胚抗原水平变化，并比较治疗疗效。结果两组病人治疗前各项血清学指标比较，均差异无统计学意义( P>0.05)。与治疗前比较，治疗后两组病人纤溶功能指标 P-选择素、血管性血友病因子( vWF)、尿激酶型纤维酶原激活物( uPA)、纤溶酶原激活剂抑制物( PAI)均显著降低，研究组分别为( 20.41±2.95)pg/L、(111.54±12.48)%、(0.79±0.08) μg/L和( 0.61±0.06)Au/mL，显著低于对照组的( 26.33±3.18)pg/L、(121.36±15.68)%、(1.05±0.11)μg/L和( 0.72±0.07)Au/mL(均 P <0.001)。与治疗前比较，治疗后两组病人凝血功能指标凝血酶原时间( PT)、纤维蛋白原( Fbg)、部分凝血活酶( APTT)、凝血酶时间( TT)均显著降低，研究组分别为( 15.09±1.85)s、(3.11±0.41)g/L、(32.01±3.58)s、(13.98±1.34)s，均显著低于对照组的(17.25±2.01)s、(4.22±0.54)g/L、(36.61±4.21)s、(15.61±1.55)s(均 P<0.001)。与治疗前比较，治疗后两组病人 T细胞亚群( CD3、 CD4、CD4/CD8)水平均显著升高，研究组分别为( 73.61±8.95)%、(41.36±5.21)%、(1.61±0.17)%，均显著优于对照组的( 55.63±7.25)%、(36.19±4.85)%、(1.28±0.15)%(均 P<0.001)。与治疗前比较，治疗后两组病人肿瘤标志物糖类抗原 199、癌胚抗原水平均显著降低，研究组分别为( 41.62±5.81)U/mL和( 8.10±0.92)μg/L，均显著低于对照组的( 63.36±7.94)U/mL和( 10.02±1.11)μg/L(P均<0.001)。治疗后研究组治疗总有效率显著高于对照组( 92.05％比 80.68%，χ2=4.82，P=0.028)。结论克岩胶囊、介入治疗结合使用可降低病人的糖类抗原 199、癌胚抗原水平，并使纤溶功能与凝血功能得到改善，临床效果良好。 |
| 英文摘要: |
| Objective To analyze the curative effect of Keyan Capsule combined with interventional therapy on patients with primary liver cancer and its influence on CA199 and CEA levels.Methods A total of 176 patients with primary liver cancer treated in Hebei Hepatopathy Hospital of Traditional Chinese Medicine from August 2019 to August 2021 were selected as research objects, andwere divided into control group and study group, with 88 cases in each group. The control group was treated with interventional therapy,and the study group was treated with Keyan Capsule on the basis of the control group. The fibrinolytic function, coagulation function, Tcell subsets, CA199, CEA levels and therapeutic effects were compared between the two groups.Results There was no significant difference in serum indexes between the two groups before treatment (P>0.05). Compared with that before treatment, the indexes of fibrinolytic function (PS, vWF, uPA and PAI) in the two groups decreased significantly after treatment. The indexes in the study group were(20.41±2.95) pg/L, (111.54±12.48) % , (0.79 ± 0.08) μg/L and (0.61±0.06) Au/mL, respectively, which were significantly lower thanthose in the control group (26.33±3.18) pg/L, (121.36±15.68) %, (1.05±0.11) μg/L, (0.72±0.07) Au/mL (all P<0.001). Compared withthose before treatment, the indexes of coagulation function (PT, FBG, APTT and TT) in the two groups were significantly lower aftertreatment. The indexes of coagulation function in the study group were (15.09±1.85) s, (3.11±0.41) g/L, (32.01±3.58) s and (13.98±1.34) s, respectively, which were significantly lower than those in the control group (17.25±2.01) s, (4.22±0.54) g/L, (36.61±4.21) s,(15.61±1.55) s (all P<0.001). The levels of T cell subsets (CD3, CD4 and CD4/CD8) in the study group were (73.61±8.95) %, (41.36±5.21) % , (1.61±0.17) % , which were significantly better than those in the control group (55.63±7.25) % , (36.19±4.85) % , (1.28±0.15) % (all P<0.001). The levels of tumor markers (CA199 and CEA) in the study group were (41.62±5.81) U/mL and (8.10±0.92) μg/L, respectively, which were significantly lower than those in the control group (63.36±7.94) U/mL, (10.02±1.11)μg/L (P<0.001). After treatment, the total effective rate of the study group was significantly higher than that of the control group (92.05 % vs. 80.68 %, χ2= 4.82, P=0.028).Conclusion The combined use of Keyan Capsule and interventional therapy can reduce the level of CA199 and CEAin patients, and improve the fibrinolytic function and blood coagulation function, and the clinical effect is good. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
